{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:24:49Z","timestamp":1795112689188,"version":"4.10.3"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"name":"Knut och Alice Wallenbergs StiftelseKnut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)"},{"name":"Lion Foundation Western Sweden"},{"name":"CancerfondenCancerfonden (Swedish Cancer Society)"},{"name":"Familjen Erling-Perssons StiftelseFamiljen Erling-Perssons Stiftelse (Erling-Persson Family Foundation)"},{"name":"ALF-VGR"},{"name":"Sj\u00f6berg Foundation"},{"name":"Biocare Strategic Research Funds"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptors (CAR) can transmit signals akin to those from activated T-cell receptors when bound to a cell surface target. CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use. However, no CAR-T therapy is currently approved for use in solid tumors. We hypothesize that the resistance of solid tumors to CAR-T can be overcome by similar means as those used to reactivate tumor-infiltrating T lymphocytes (TIL), for example, by cytokines or immune checkpoint blockade. Here we demonstrate that CAR-T cells directed against HER2 can kill uveal and cutaneous melanoma cells in vitro and in vivo. Curative effects in vivo were only observed in xenografts grown in a NOD\/SCID IL2 receptor gamma (NOG) knockout mouse strain transgenic for human IL2. The effect was target-specific, as CRISPR\/Cas9-mediated disruption of HER2 in the melanoma cells abrogated the killing effect of the CAR-T cells. The CAR\u2013T cells were also able to kill melanoma cells from patients resistant to adoptive T-cell transfer (ACT) of autologous TILs. Thus, CAR-T therapy represents an option for patients that do not respond to immunotherapy with ACT of TIL or immune checkpoint blockade. In addition, our data highlight the use of IL2 transgenic NOG mice as models to prove efficacy of CAR-T-cell products, possibly even in a personalized manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>These findings demonstrate that a novel humanized mouse model can help clinical translation of CAR-T cells against uveal and cutaneous melanoma that do not respond to TIL therapy or immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-18-3158","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T16:06:18Z","timestamp":1546963578000},"page":"899-904","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy\u2013Resistant Human Melanoma in IL2 Transgenic NOD\/SCID IL2 Receptor Knockout Mice"],"prefix":"10.1158","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-3060","authenticated-orcid":false,"given":"Elin M.V.","family":"Forsberg","sequence":"first","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"2Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias F.","family":"Lindberg","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"2Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-5369","authenticated-orcid":false,"given":"Henrik","family":"Jespersen","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"3Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Als\u00e9n","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"2Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0355","authenticated-orcid":false,"given":"Roger Olofsson","family":"Bagge","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"2Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[{"name":"4The Center of Cancer Immunotherapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"4The Center of Cancer Immunotherapy, Copenhagen University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Nilsson","sequence":"additional","affiliation":[{"name":"5Department of Pathology, Institute of Biomedicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"3Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Nilsson","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"2Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas A.","family":"Nilsson","sequence":"additional","affiliation":[{"name":"1The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden."},{"name":"2Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"2022061706270736500_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2022061706270736500_bib6","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"2022061706270736500_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41467-017-00786-z","article-title":"Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model","volume":"8","author":"Jespersen","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706270736500_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022061706270736500_bib11","doi-asserted-by":"crossref","first-page":"1758834018757175","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2022061706270736500_bib12","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.18632\/oncotarget.2445","article-title":"Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions","volume":"5","author":"Einarsdottir","year":"2014","journal-title":"Oncotarget"},{"key":"2022061706270736500_bib13","doi-asserted-by":"crossref","first-page":"23801","DOI":"10.18632\/oncotarget.8181","article-title":"Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts","volume":"7","author":"Bhadury","year":"2016","journal-title":"Oncotarget"},{"key":"2022061706270736500_bib14","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061706270736500_bib15","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022061706270736500_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2022061706270736500_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706270736500_bib18","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","article-title":"Acquired immune resistance follows complete tumor regression without loss of target antigens or IFN\u03b3 signaling","volume":"77","author":"Donia","year":"2017","journal-title":"Cancer Res"},{"key":"2022061706270736500_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell Death Dis"},{"key":"2022061706270736500_bib20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41419-018-0865-6","article-title":"A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma","volume":"9","author":"Einarsdottir","year":"2018","journal-title":"Cell Death Dis"},{"key":"2022061706270736500_bib21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"key":"2022061706270736500_bib22","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022061706270736500_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur J Immunol"},{"key":"2022061706270736500_bib24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"2022061706270736500_bib25","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/5\/899\/2789861\/899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/5\/899\/2789861\/899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:33:35Z","timestamp":1655476415000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/79\/5\/899\/640514\/HER2-CAR-T-Cells-Eradicate-Uveal-Melanoma-and-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3,1]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-3158","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22423386","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423389","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423386.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423380","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423383","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423380.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423374.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423389.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423377.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423383.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6511488.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6511488","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}